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Objectives We sought to determine clinical and demographic predictors of recovery of left ventricular function for subjects
with recent onset cardiomyopathy (ROCM).
Background Although ROCM is a frequent reason for consultation and transplantation referral, its prognosis and natural his-
tory on contemporary therapy are unknown.
Methods In the multicenter IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study, subjects with a left ven-
tricular ejection fraction (LVEF) of 0.40, fewer than 6 months of symptom duration, and an evaluation consis-
tent with idiopathic dilated cardiomyopathy or myocarditis were enrolled. LVEF was reassessed at 6 months, and
subjects were followed up for 4 years. LVEF and event-free survival were compared by race, sex, and clinical phe-
notype.
Results The cohort of 373 persons was 38% female and 21% black, with a mean age of 45  14 years. At entry, 91%
were receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and 82% were receiv-
ing beta-blockers, which increased to 92% and 94% at 6 months. LVEF was 0.24  0.08 at entry and 0.40 
0.12 at 6 months (mean increase: 17  13 ejection fraction units). Transplant-free survival at 1, 2, and 4 years
was 94%, 92%, and 88%, respectively; survival free of heart failure hospitalization was 88%, 82%, and 78%, re-
spectively. In analyses adjusted for sex, baseline LVEF, and blood pressure, LVEF at 6 months was significantly
lower in blacks than in nonblacks (p  0.02). Left ventricular end-diastolic diameter at presentation was the
strongest predictor of LVEF at 6 months (p  0.0001).
Conclusions Outcomes in ROCM are favorable but differ by race. Left ventricular end-diastolic diameter by transthoracic echo
at presentation was most predictive of subsequent myocardial recovery. (Genetic Modulation of Left Ventricular
Recovery in Recent Onset Cardiomyopathy; NCT00575211) (J Am Coll Cardiol 2011;58:1112–8) © 2011 by
the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.033Idiopathic dilated cardiomyopathy remains an important
cause of systolic heart failure and the most common cause of
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2011, accepted May 10, 2011.heart failure in young people referred for cardiac transplan-
tation (1). With a prevalence estimated at 36 cases per
100,000 (2), this disorder affects well over 100,000 people in
the United States alone. An inflammatory pathogenesis is
suspected (3); however, endomyocardial biopsy demon-
strates inflammation in only a small subset of patients (4).
Treatment with immune modulatory therapy has not
proven effective for recent onset cardiomyopathy (ROCM)
(5,6), nor in the subset with cellular myocarditis (7).
Myocardial recovery occurs in one-third of subjects with
ROCM, defined as fewer than 6 months of cardiac symp-
toms. Most previous reports (8) in ROCM predate the
widespread use of beta-blockers, and the prognosis and natural
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initiated a multicenter investigation of myocardial recovery in
subjects with ROCM to determine the demographic and
clinical predictors of subsequent left ventricular recovery.
Methods
The IMAC (Intervention in Myocarditis and Acute
Cardiomyopathy)-2 study was a prospective, multicenter
investigation of myocardial recovery in subjects with recent
onset (i.e., acute) nonischemic dilated cardiomyopathy and
myocarditis that enrolled subjects at 16 centers (Online
Appendix) from May 2002 through December 2008. All
subjects had a left ventricular ejection fraction (LVEF) of
0.40 or less by echocardiography and symptoms of 6
months in duration. Informed consent was obtained from
all subjects, and the protocol was approved by the institu-
tional review boards of all participating centers.
Demographic information included self-designated race
(white, black, Asian, or other). Subjects underwent angiog-
raphy or noninvasive screening to exclude coronary artery
disease and transthoracic echocardiography to rule out
valvular disease. Patients with significant diabetes (requiring
therapy with insulin or an oral agent for more than 1 year),
uncontrolled hypertension (diastolic blood pressure more
than 95 mm Hg or systolic blood pressure more than 160
mm Hg), suspected alcoholism, tachycardia-induced car-
diomyopathy, uncorrected thyroid disease, or systemic dis-
orders with associated cardiomyopathy, such as lupus ery-
thematosus, hemochromatosis, or sarcoidosis, were
excluded. Right ventricular endomyocardial biopsy was not
required based on current practice guidelines (9).
LVEF was assessed by transthoracic echocardiography at
entry and at 6 months, and patients were followed up for up
to 48 months. All deaths and hospitalizations were adjudi-
cated by an independent events committee. The primary
outcome was change in LVEF from baseline to 6 months.
Secondary outcomes included transplant-free survival and
hospitalization-free survival.
Echocardiography. Echocardiographic studies were reviewed
in a blinded fashion by a core laboratory at the University of
Pittsburgh. Digital routine grayscale 2-dimensional cine
loops were obtained at frame rates of 40 to 90 Hz (mean: 60
 15 Hz) from standard apical 4-chamber, 2-chamber, and
long-axis views. The left ventricle (LV) volume and LVEF
were assessed by biplane Simpson’s rule using manual
tracing of digital images. Left ventricular end-diastolic
diameter (LVEDD) was assessed in the parasternal long-
axis view.
Statistical analysis. Demographic and clinical characteris-
tics were compared by sex and race (black vs. nonblack),
with continuous variables compared by Student t tests and
categorical variables compared by use of the Fisher exact
test. For the analysis of LVEDD and myocardial recovery,
comparisons first were made based on a simple arbitrary
division chosen for clinical usefulness. Subjects weregrouped based on LVEDD at pre-
sentation into those with minimal
dilation, 6.0 cm, moderate dila-
tion, 6.0 to 7.0 cm, and severe
dilation, 7.0 cm. Analysis then
was repeated using sex-specific ter-
tiles. This included use of general
linear models and a 1-degree of
freedom linear contrast (coded
1, 0, 1) to evaluate whether the
extent of myocardial recovery var-
ied monotonically with respect to
tertiles of LVEDD. In multivari-
ate analysis, multiple linear regres-
sion was used to identify independent predictors of change in
LVEF at 6 months (i.e., verified as approximately normally
distributed). Covariates were selected by use for stepwise
selection (forward) with an entry and retainment p value of
0.05, and age was included regardless of statistical significance.
Before assessment of main effects, the interaction between race
and both systolic and diastolic blood pressure was examined.
Survival analysis methods were based on 3 endpoints:
death, death or transplantation, and a composite endpoint
that included death, transplantation, and heart failure hos-
pitalization. The Kaplan-Meier method was used to esti-
mate event-free survival and curves compared by the log-
rank test. In multivariate analysis, Cox regression was used
to estimate adjusted hazard ratios for the endpoints death/
transplantation and the composite endpoint. Stepwise se-
lection (forward) was used to identify independent predic-
tors of these endpoints, with race (black, nonblack) and
diastolic blood pressure (more or less than the median of 70
mm Hg) combined into 4 groups to yield estimates of
interaction effects (because of the significant interaction).
The proportional hazards assumption of invariant relative
risk was tested formally and was found to be upheld for all
variables and endpoints assessed with 2 minor exceptions.
For risk of death/transplantation, the hazard ratio associated
with New York Heart Association (NYHA) functional
class IV was more pronounced in the first year of follow-up;
for risk of the composite endpoint, there was an indication
that risk increased in a nonproportional manner over
follow-up among black patients with diastolic blood pres-
sure of 70 mg/dl at baseline. For these 2 exceptions,
separate risk estimates were reported for early follow-up.
Results
The cohort of 373 subjects was 21% (n 80) black and 38%
(n  143) women, including 39 (10%) with peripartum
cardiomyopathy. The mean age was 45  14 years, LVEF
was 0.24  0.08, symptom duration was 2.2  1.7 months,
and percent NYHA functional class I, II, III, and IV was
18%, 46%, 29%, and 7%, respectively. Forty-four (12%)
Abbreviations
and Acronyms
LV  left ventricle/
ventricular
LVEDD  left ventricular
end-diastolic diameter
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Association
ROCM  recent onset
cardiomyopathysubjects underwent an endomyocardial biopsy that revealed
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10 (2.6%) subjects.
Therapy at entry included an angiotensin-converting
enzyme inhibitor or angiotensin receptor blocker in 91%,
beta-blocker in 82%, aldosterone receptor antagonist in
27%, and loop diuretic in 67% (predominantly furosemide
in 96%, mean daily dose: 57  43 mg). At entry, 28 (7.5%)
subjects had an implantable cardiac defibrillator (implant-
able cardioverter-defibrillator), 28 (7.5%) were receiving
intravenous inotropic therapy, 3 (0.8%) had an intra-aortic
balloon pump, and 6 (1.6%) had an LV assist device.
At 6 months, 92% were receiving an angiotensin-
converting enzyme inhibitor or angiotensin receptor
blocker, 94% were receiving beta-blockers, 20% had an
implantable cardioverter-defibrillator, and the percent of
subjects with NYHA functional class I, II, III, and IV was
45%, 44%, 9%, and 1%, respectively. The mean LVEF was
0.40 0.12 (n 327), with an increase of 17 13 ejection
raction units (n  312). Overall, 70% demonstrated an
ncrease at 6 months of at least 10 ejection fraction units,
nd 39% demonstrated an increase of 20 U or more. Forty
ercent had an LVEF of 0.45 or more at 6 months, and for
5%, the LVEF had normalized (0.50 or more). The
ercent of subjects whose LVEF normalized differed by sex
men: 20%, women: 34%, p  0.004) with a trend toward
less recovery in blacks (blacks: 18%, nonblacks: 27%, p 
0.14). Combining the demographic factors, an LVEF of
0.50 or more at 6 months was most likely in white women
(38%), least likely in black men (15%), and intermediate in
white men (21%) and black women (20%).
The mean follow-up was 2.2  1.4 years. During
follow-up, there were 14 deaths (4%), 17 transplantations
(5%), 45 hospitalizations for heart failure (12%) in the
absence of death or transplantation, and 62 (17%) hospital-
izations for heart failure in aggregate with a survival at 1, 2,
and 4 years of 98%, 96%, and 94%, respectively, transplant-
free survival of 94%, 92%, and 88%, respectively (Fig. 1A),
and survival free of the composite endpoint of 88%, 82%,
and 78%, respectively. Prognosis was dependent on func-
tional class at presentation, with percent transplant-free
survival at 1 year for NYHA functional class I, II, III, and
IV of 100%, 98%, 87%, and 75% (p  0.0001) (Fig. 1B). A
similar finding was evident based on hemodynamic support,
because more subjects receiving intravenous inotropic ther-
apy at entry died (18% vs. 3%) or underwent transplantation
(18% vs. 4%) during follow-up (p  0.001).
Sex and outcomes. Myocardial recovery was more evident
in women, with a similar baseline LVEF of 0.24  0.08 in
women versus 0.23  0.08 in men (p  0.09) and a larger
LVEF at 6 months of 0.43  0.12 in women versus 0.39 
.12 in men (p  0.004) (Table 1). Transplant-free survival
as significantly better in women (1-, 2-, and 4-year percent
ransplant-free survival for women: 96%, 96%, and 96%, for
en: 93%, 90%, and 84%, p  0.03), driven by a markedifference in survival (p  0.003). aace and outcomes. The cohort included 80 black subjects
21%) and 293 nonblack subjects (79%: 272 white, 9 Asian,
nd 12 other). Medical therapy with angiotensin-converting
nzyme inhibitors and beta-blockers was comparable (Table 1).
ydralazine and nitrates were received by 9% of blacks and
% of nonblacks (p 0.005). The black cohort was younger
range: 42  12 years, nonblack: 46  14 years, p  0.02),
ith higher diastolic blood pressure at entry (mean diastolic
or blacks: 74  13 mm Hg, mean diastolic for nonblacks:
0  12 mm Hg, p  0.005, and systolic for blacks: 115 
19 mm Hg, systolic for nonblacks: 111  19 mm Hg, p 
.10) and heart rate (blacks: 87  17 beats/min, nonblacks:
2  17 beats/min, p  0.02). Aldosterone receptor
antagonist use was greater in blacks (p  0.007) and was
driven by use in subjects with advanced heart failure (for
NYHA functional class III and IV: 53% of blacks on
therapy vs. 28% of nonblacks, p  0.01).
LVEF was similar at baseline (blacks: 0.23  0.08,
nonblacks: 0.24  0.08, p  0.33), but was lower in blacks
Figure 1 Transplant-Free Survival
Graphs showing transplant-free survival in (A) the overall cohort (n  373) and
(B) stratified by New York Heart Association (NYHA) functional class (for
classes I, II, III, and IV, n  68, 172, 108, and 25, respectively). Higher func-
tional class is associated with poorer event-free survival (p  0.0001).t 6 months (blacks: 0.37  0.13, nonblacks: 0.41  0.12,
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transplant-free survival (1, 2, and 4 years, black: 90%, 85%,
and 72%, nonblacks: 95%, 93%, and 92%, p  0.01) (Fig. 2A)
nd survival free of the composite endpoint (1, 2, and 4
ears, black: 83%, 69%, and 50%, nonblacks: 90%, 86%,
3%, p  0.001) (Fig. 2B). Similar results were observed
hen the nonblack group was restricted to the 272 (93.5%)
f 293 subjects with self-designated race classified as white
data not shown).
VEDD and myocardial recovery. Overall the mean
VEDD was 6.3  1.0 cm. When dividing subjects into
hose with minimal dilation (group 1: LVEDD  6.0 cm,
 125), moderate dilation (group 2: 6.0 to 7.0 cm, n 
39), or severe dilation (group 3:  7.0 cm, n  67), LVEF
t baseline (groups 1, 2, and 3: 0.27  0.08, 0.23  0.08,
nd 0.20  0.07, respectively, p  0.0001), LVEF at 6
onths (groups 1, 2, and 3: 0.45  0.11, 0.40  0.11, and
.32  0.12, respectively, p  0.0001), and change in
VEF (groups 1, 2, and 3: 0.19  0.12, 0.17  0.13, and
.13  0.13, respectively, p  0.005) were greatest for
group 1, intermediate for group 2, and lowest for group 3
(Fig. 3A). This analysis was repeated using sex-specific
tertiles, and a similar association of smaller LVEDD with
greater recovery was evident for both women (Fig. 3B) and
Demographic and Clinical Characteristics by SeTable 1 Demographic and Clinical Characte
By Sex
All
(n  373)
Age (yrs) 45 14
Black 21.5
NYHA functional class I/II/III/IV 18/46/29/7
LVEF baseline 0.24 0.08
LVEF at 6 months 0.40 0.12
BP systolic 112 19
BP diastolic 71 13
Heart rate 83 17
Therapy at entry
ACE inhibitor 82.3
Aldosterone receptor antagonist 27.4
Beta-blocker 82.0
By Race
Nonb
(n 
Age (yrs) 46
Female 36
NYHA functional class I/II/III/IV 20/46
LVEF baseline 0.24
LVEF at 6 months 0.41
BP systolic 111
BP diastolic 70
Heart rate 82
Therapy at entry
ACE inhibitor 82
Aldosterone receptor antagonist 23
Beta-blocker 80
Values are mean  SD or %.
ACE  angiotensin converting enzyme; BP  blood pressure; LVEFmen (Fig. 3C). sMultivariate analyses. Independent predictors of LVEF at
6 months of follow-up are provided in rank order in Table 2.
A smaller LVEDD at baseline was associated with higher
LVEF at 6 months (p  0.0001), independent of sex
(p  0.75). Higher systolic blood pressure at baseline also
was associated with LVEF at 6 months (p  0.001),
hereas black race (p 0.02) and higher NYHA functional
lass (p  0.04) were associated with lower LVEF at 6
onths. These associations occurred independent of base-
ine LVEF, which was included as a covariate and was not
ssociated with LVEF at 6 months (p  0.32). In total, the
7 variables included in the multiple linear regression model
explained 25% of the variation in LVEF at 6 months. The
interaction between race and systolic blood pressure (p 
0.96), as well as diastolic pressure (p  0.63), was not
statistically significant (data not shown), indicating that
the effect of race was independent of baseline blood
pressure. Similar results were observed when the outcome
(dependent) variable was absolute change in LVEF be-
tween baseline and 6 months (Table 2).
Predictors of death/transplantation and the composite
endpoint are provided in Table 3. As seen, NYHA
unctional class IV (adjusted hazard ratio: 9.41) and black
ace (adjusted hazard ratio: 2.78) were associated with a
Races by Sex and Race
Men
(n  230)
Women
(n  143) p Value
46 14 43 14 0.01
19.1 25.2 0.19
20/45/27/7 15/48/31/6 0.53
0.23 0.08 0.24 0.08 0.09
0.39 0.12 0.43 0.12 0.004
113 20 111 17 0.27
71 13 71 13 0.97
83 17 83 16 0.86
84.3 79.0 0.21
29.1 24.5 0.34
80.9 83.9 0.49
Black
(n  80)
42 12 0.02
40.0 0.19
11/46/40/3 0.02
0.23 0.08 0.33
0.37 0.13 0.007
115 19 0.10
74 13 0.005
87 17 0.02
80.0 0.51
40.0 0.007
87.5 0.19
entricular ejection fraction; NYHA  New York Heart Association.x andristic
lack
293)
14
.5
/26/8
0.08
0.12
19
12
17
.9
.9
.5ignificantly higher risk of death/transplantation over
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hazard ratio: 0.34) was associated with a significantly
lower risk of death/transplantation. Compared with
white patients with diastolic blood pressure of 70 mg/dl
or more at baseline, black patients with diastolic blood
pressure of more than 70 mg/dl has an estimated 5-fold
higher risk of death/transplantation. Results generally
were consistent for the broader outcome of risk of the
composite endpoint; however, black patients were at
higher risk than white patients regardless of baseline
diastolic blood pressure.
Discussion
Recent onset dilated cardiomyopathy remains a challenging
diagnosis for patients and clinicians alike and frequently
results in referral to tertiary centers. The current study
Figure 2 Clinical Outcomes by Race
(A) Graph showing transplant-free survival (black [n  80] vs. nonblack
[n  293]). Event-free survival is worse in black patients (p  0.01).
(B) Graph showing survival free of heart failure hospitalization (black [n  80]
vs. nonblack [n  293]). Event-free survival is worse in black patients
(p  0.001).demonstrates that there is substantial improvement inLVEF evident for most subjects over the first 6 months.
Despite concerns, the short-term the prognosis is favorable,
with a transplant-free survival of 88% at 4 years.
Figure 3 Myocardial Recovery by LVEDD
(A) Bar graph showing myocardial recovery by left ventricular end-diastolic
diameter (LVEDD) for the entire cohort: solid bars  LVEDD 6.0 cm; shaded
bars  LVEDD 6.0 to 7.0 cm; open bars  LVEDD 7.0 cm. Left ventricular
ejection fraction (LVEF) at entry (p  0.0001), LVEF at 6 months (p  0.0001),
and left ventricle change (p  0.005) all were significantly greater with smaller
LVEDD. (B) Bar graph showing myocardial recovery by LVEDD for women: solid
bars  LVEDD 5.5 cm; shaded bars  LVEDD 5.6 to 6.1 cm; open bars 
LVEDD 6.1 cm. The LVEF at entry (p  0.0004), LVEF at 6 months (p 
0.0001), and left ventricle LV change (p  0.008). (C) Bar graph showing myo-
cardial recovery by LVEDD for men: solid bars  LVEDD 6.1 cm; shaded bars
 LVEDD 6.2 to 6.9 cm; open bars  LVEDD 6.9 cm. The LVEF at entry (p 
0.0001), LVEF at 6 months (p  0.0001), and left ventricle LV change (p 
0.37). The label on each bar represents mean LVEF for the subset. Error bar
represents standard deviation.
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and the percent of patients normalizing their ejection
fraction (25%) in the current series does not differ signifi-
cantly from that of previous investigations (4,6,8). However,
the percentage of subjects experiencing at least moderate
recovery of LV function, that is, 10 ejection fraction units or
more, has improved dramatically from one third in an older
series (4,8) to one-half in the previous Intervention in
Myocarditis and Acute Cardiomyopathy trial (6), to nearly
70% of subjects in the current cohort. Given the impact of
beta-blockers in chronic nonischemic cardiomyopathy
(10,11), the widespread improvements in LVEF in the
Predictors of LVEF and Changein LVEF at 6 Months (n  292)Table 2 Predictors of LVEF and Changein LVEF at 6 Months (n  292)
Variable t Value
Standardized
Coefficient
Semipartial2
Correlation p Value
LVEF
LVEDD –6.98 –0.41 0.13 0.0001
Systolic BP 3.30 0.18 0.03 0.001
Black race –2.39 –0.12 0.01 0.02
NYHA functional class –2.10 –0.11 0.01 0.04
Age –1.25 –0.07 0.004 0.21
Baseline LVEF 1.00 0.06 0.003 0.32
Female 0.32 0.02 0.0003 0.75
Adjusted R2  0.25
Change in LVEF
Baseline LVEF –10.91 –0.59 0.28 0.0001
LVEDD –6.98 –0.39 0.11 0.0001
Systolic BP 3.30 0.17 0.03 0.001
Black race –2.39 –0.12 0.01 0.02
NYHA functional class –2.10 –0.11 0.01 0.04
Age –1.25 –0.06 0.004 0.21
Female 0.32 0.02 0.0002 0.75
Adjusted R2  0.32
LVEDD  left ventricular end-diastolic diameter; other abbreviations as in Table 1.
Predictors of Death/Transplantation and HF HosTable 3 Predictors of Death/Transplantatio
Predictor
Death/Transplantation
Adjusted HR 95% CI
NYHA functional class
II (vs. I) 1.19 0.25–5.71
III (vs. I) 4.16 0.93–18.6
IV (vs. I) 9.41* 1.83–48.3
Age (per 10 yrs) 0.77 0.59–1.01
Female 0.34 0.14–0.83
Heart rate (per 10 beats) — —
Race and diastolic BP§
White, DBP 70 mg/dl 2.07 0.79–5.43
Black, DBP 70 mg/dl 2.11 0.41–10.8
Black, DBP 70 mg/dl 4.97 1.69–14.6
*The estimated adjusted hazard ratio in the first 2 years of follow-up
compared with the average risk estimate of 9.41 estimated for the e
variable was 0.0001. ‡The p value for NYHA functional class as an o
white classification includes all races self-reported other than black. 
(95% CI: 0.47 to 6.65), indicating lower risk early in follow-up compar
period.
CI  confidence interval; DBP  diastolic blood pressure; HF  heart failucurrent investigation can be attributed in part to their
extensive use in this cohort.
An inflammatory pathogenesis is postulated for sub-
jects with so-called reversible cardiomyopathy, in which
the recovery ensues when the inflammatory event resolves
(12). Indeed, for subjects with histological confirmation
of lymphocytic myocarditis, the mean LVEF at 6 months
was 0.49  0.08. Although myocardial inflammation may
be a potential marker of reversibility, additional method-
ologies, including cardiac magnetic resonance and novel
peripheral biomarkers, may be more effective than endo-
myocardial biopsy at delineating reversible inflammatory
myocarditis (13).
Women had better outcomes than men in terms of
LVEF at 6 months and transplant-free survival. A similar
trend toward better recovery in women was seen in the first
IMAC trial. Analysis of myocardial gene expression in that
trial demonstrated that activation of apoptotic pathways was
associated inversely with recovery (14) and that this activa-
tion was less evident in women. The recovery of LVEF in
the current study is consistent with investigations in chronic
heart failure in which women generally have better out-
comes than their male counterparts (15).
Self-identified black subjects demonstrated less recovery
and markedly worse transplant-free survival. The impact of
race in recent onset cardiomyopathy again parallels findings
in chronic heart failure (16). It long has been recognized
that hypertension is more prevalent in blacks as a cause of
heart failure. Although multivariate analysis did not suggest
that racial differences by race could be attributed to blood
pressure, this was based a single baseline measurement, and
does not address the potential impact of chronic hyperten-
sion. Whether outcomes by race reflect a differential
genomic response to therapy or other socioeconomic vari-
ables will require further analysis.
izationHF Hospitalization
373) HF Hospitalization (n  373)
p Value Adjusted HR 95% CI p Value
0.83 1.04 0.43–2.48 0.94
0.06 1.52 0.62–3.74 0.36
0.007† 3.50 1.22–10.02 0.02‡
0.06 0.85 0.70–1.04 0.12
0.02 0.57 0.32–0.99 0.05
— 1.21 1.03–1.43 0.02
0.14 1.85 0.97–3.53 0.06
0.38 3.65 1.51–8.82 0.004
0.004 2.94 1.37–6.32 0.006
8.2 (95% CI: 2.13 to 155.5), indicating higher risk early in follow-up
llow-up period. †The p value for NYHA functional class as an ordered
variable was 0.01. §The referent group is white, DBP70 mg/dl; the
imated adjusted hazard ratio in the first years of follow-up was 1.76
the average risk estimate of 3.65 estimated for the entire follow-uppitaln and
(n 
3
2
4
0
was 1
ntire fo
rdered
The est
ed withre; HR  hazard ratio; other abbreviation as in Tables 1 and 2.
11
1
1
1
1
1
1
1118 McNamara et al. JACC Vol. 58, No. 11, 2011
Outcomes in Recent Onset Cardiomyopathy September 6, 2011:1112–8In terms of the initial assessment, LVEDD was most
predictive, because less LV enlargement at presentation
predicted a greater LVEF at 6 months. In a recent analysis
of subjects supported with a left ventricular assist device,
myocardial recovery occurred in 12% of subjects overall, but
33% of subjects with LVEDD 6.0 cm (17). Smaller LV
size likely is a marker of a more reversible cardiac patho-
logical condition and LVEDD remains a simple standard
echo measure routinely reported that can provide immediate
clinical guidance in predicting recovery potential.
Study limitation. A limitation of this study is the overall
low number of so-called hard events in the analysis (i.e.,
death/transplantation). The net consequence of this is
relatively imprecise estimates of long-term risk of death/
transplantation and heart failure hospitalization. This lim-
itation should be kept in mind when interpreting the
relative predictive value of individual variables.
Conclusions
Contemporary heart failure therapy has changed the natural
history of recent onset cardiomyopathy from a rapidly
progressive disorder to a more manageable condition with
an overall favorable prognosis. Indeed, most subjects have
significant improvements in LVEF during the first 6
months. Recognition of this recovery potential is essential,
and advanced therapies such as cardiac transplantation
should not be undertaken until clinicians observe the early
clinical course to determine the degree of recovery. Al-
though these results are encouraging, outcomes remain
heterogeneous; in particular, recovery and survival were
poorer in black subjects. The basis for these apparent racial
differences is unknown, and additional investigation is
required to delineate the biologic and genomic determinants
of myocardial recovery in ROCM.
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APPENDIX
For a full list of the IMAC Investigators,
please see the online version of this article.
